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Abbreviations: EBV - Epstein-Barr virus, GCV - ganciclovir, HDAC - histone 
deacetylase, SAHA -suberoylanilide hydroxamic acid, NPC - nasopharyngeal 
carcinoma and GC - gastric carcinoma 
 
Journal Category: Cancer therapy 
 
Novelty and Impact: Pharmacological reactivation of Epstein-Barr virus (EBV) lytic 
cycle is being explored as a potential therapeutic strategy against EBV-associated 
diseases. This study demonstrates that a class I histone deacetylase (HDAC) inhibitor, 
romidepsin, can potently induce EBV lytic cycle through inhibition of HDAC-1/-2/-3 
and activation of protein kinase C-δ and confer cytotoxicity of ganciclovir in 
EBV-positive epithelial malignancies. The data warrant further application of 
romidepsin for the investigation of EBV life cycle and treatment of EBV-associated 
cancers. 
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Abstract 
Pan-histone deacetylase (HDAC) inhibitors, which inhibit eleven HDAC 
isoforms, are widely used to induce EBV lytic cycle in EBV-associated cancers in 
vitro and in clinical trials. Here, we hypothesized that inhibition of one or several 
specific HDAC isoforms by selective HDAC inhibitors could potently induce EBV 
lytic cycle in EBV-associated malignancies such as nasopharyngeal carcinoma (NPC) 
and gastric carcinoma (GC). We found that inhibition of class I HDACs, particularly 
HDAC-1, -2 and -3, was sufficient to induce EBV lytic cycle in NPC and GC cells in 
vitro and in vivo. Among a panel of selective HDAC inhibitors, the FDA-approved 
HDAC inhibitor romidepsin was found to be the most potent lytic inducer, which 
could activate EBV lytic cycle at ~0.5 to 5 nM (versus ~800 nM achievable 
concentration in patients’ plasma) in more than 75% of cells. Up-regulation of 
p21
WAF1
, which is negatively regulated by class I HDACs was observed prior to the 
induction of EBV lytic cycle. The up-regulation of p21
WAF1
 and induction of lytic 
cycle were abrogated by a specific inhibitor of PKC-δ but not the inhibitors of PI3K, 
MEK, p38 MAPK, JNK, or ATM pathways. Interestingly, inhibition of HDAC-1, -2 
and -3 by romidepsin or shRNA knockdown could confer susceptibility of 
EBV-positive epithelial cells to the treatment with ganciclovir. In conclusion, we 
demonstrated that inhibition of class I HDACs by romidepsin could potently induce 
EBV lytic cycle and mediate enhanced cell death with ganciclovir, suggesting 
potential application of romidepsin for the treatment of EBV-associated cancers. 
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Introduction: 
Epstein-Barr virus (EBV) is a gamma herpesvirus, which infects more than 90% 
of the world population. It is closely associated with several types of malignancies, 
such as endemic Burkitt’s lymphoma, Hodgkins lymphoma, nasal NK/T-cell 
lymphoma, nasopharyngeal carcinoma (NPC), and gastric carcinoma (GC).
1, 2
 In these 
EBV-associated malignancies, the virus persists in tightly latent forms with restricted 
expression of viral latent proteins in every tumor cell.
1, 3
 Reactivation of the latent 
virus into lytic cycle can lead to expression of over 70 viral proteins of higher 
immunogenicity and replication of viral genomes inside host cells. Despite the strong 
association with various cancers, current chemotherapy regimens ignore the 
EBV-positive status of the associated tumours due to difficulty in targeting the latent 
virus in these tumours.  
Pharmacological reactivation of EBV lytic cycle to confer susceptibility to 
antiviral drugs is being explored as a potential therapeutic strategy against the 
EBV-associated diseases.
4
 Studies have shown that a nucleoside-type antiviral drug 
ganciclovir (GCV) could be converted from an inactive form to cytotoxic form, when 
they are phosphorylated by the viral lytic protein kinase BGLF4.
5
 The concept of this 
lytic induction therapy began in the treatment of EBV-positive lymphoma with 
combination of histone deacetylase (HDAC) inhibitors such as arginine butyrate or 
valproic acid (VPA) with GCV.
6
 Feng et al. further showed that combination of 
chemotherapy and VPA could induce EBV lytic cycle and sensitize EBV-positive 
epithelial tumours to GCV treatment.
7
 Recently, a clinical trial of the lytic induction 
therapy using combination of gemcitabine, VPA, and GCV was carried out in three 
NPC patients and demonstrated improved clinical outcomes.
8
 Since the killing effect 
of GCV relies on expression of BGLF4, the efficacy of this treatment strategy greatly 
depends on the efficiency and specificity of lytic induction. The development of more 
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specific and potent lytic inducing agents will aid its translation into clinical use.  
Histone deacetylases (HDACs) are over-expressed in various types of cancer 
cells. The HDACs can repress the transcription of different cellular and viral genes. 
Mammalian HDACs can be categorized into four groups, including the class I 
(HDAC-1, -2, -3 and -8), class II (HDAC-4, -5, -6, -7, -9 and -10), class III (SIRT-1-7) 
and class IV HDACs (HDAC-11).
9-12
 HDAC inhibitors targeting different 
combinations of HDAC isoforms have been engaged into different stages of clinical 
trials for the treatment of cancers.
13
 To date, two HDAC inhibitors, including 
suberoylanilide hydroxamic acid (SAHA) and romidepsin have been approved by the 
Food and Drug Agency (FDA) for treatment of cutaneous T-cell lymphoma and 
peripheral T-cell lymphoma, respectively.
14, 15
 Pan-HDAC inhibitors, which inhibit 
class I, II and IV HDAC isoforms, including trichostatin A, sodium butyrate, and VPA, 
are widely used to induce EBV lytic cycle in EBV-associated cancers in vitro.
7, 8, 16, 17
 
We have reported that pan-HDAC inhibitors such as SAHA can trigger the switch of 
EBV from latent to lytic cycle and mediate enhanced killing of EBV-positive 
epithelial cancer cells, including those of NPC and GC.
16, 17
 However, the effect of 
several potentially more potent and selective HDAC inhibitors on EBV lytic cycle 
reactivation is still unknown. 
In this study, we hypothesized that inhibition of one or several specific HDAC 
isoforms by selective HDAC inhibitors can potently induce EBV lytic cycle in 
EBV-positive NPC and GC cells. We investigated the effects of different selective 
HDAC inhibitors, which target different combinations of HDAC isoforms, for their 
abilities to induce EBV lytic cycle in EBV-positive NPC and GC cells. We also 
examined the potential mechanisms related to the EBV lytic reactivation and 
investigated the combinatorial effects of the specific HDAC inhibitors with 
ganciclovir on the killing of EBV-positive NPC and GC cells.  
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Materials and Methods: 
Cell cultures 
AGS and AGS-BDneo are paired Epstein-Barr virus (EBV)-negative and recombinant 
EBV infected GC cell lines, respectively.
18
 SNU-719 is a GC cell line containing 
native EBV genomes (purchased from the Korean Cell Line Bank).
19, 20
 HONE1 and 
HA are paired EBV-negative and recombinant EBV infected NPC cell lines, 
respectively.
21, 22
 C666-1 is an EBV-positive NPC cell line that harbors native EBV 
genomes.
23
 AGS-BX1 and HONE1-EBV are generated by infecting AGS and HONE1 
cells with recombinant EBV genomes expressing green fluorescent protein.
18, 21, 22
 
The cell lines were authenticated with an AmpF/STR Identifiler PCR Amplication Kit 
(Applied Biosystems, Foster City, CA), according to the manufacturer’s protocol. The 
data were analyzed by GeneScan and GeneMapper
TM
 ID Software (Applied 
Biosystems, Foster City, CA). The cells were cultured as previously described.
17, 24
 
G418 was added to maintain the recombinant EBV in AGS-BDneo, AGS-BX1, HA 
and HONE1-EBV cells in culture flasks. To a oid any unexpected interaction 
between G418 and drugs, G418 was not added during drug treatment. 
 
Chemicals 
The selective HDAC inhibitors including romidepsin, apicidin, MS-275, droxinostat 
and PCI34051 were purchased from Selleck (Selleck Chemicals, Houston, TX); 
CAY10603 and SAHA were purchased from Cayman (Cayman Chemicals, Ann 
Arbor, MI). The anti-viral drug ganciclovir (GCV) was purchased from Sigma 
(Sigma-Aldrich, St. Louis, MO). The pathway blockers including LY294002 (PI3K 
inhibitor), PD98059 (MEK inhibitor), SP600125 (JNK inhibitor), SB202190 (p38 
MAPK inhibitor), and rottlerin (PKC-δ inhibitor) were purchased from Calbiochem 
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(Calbiochem, San Diego, CA); KU-55933 (ATM inhibitor) was purchased from 
Selleck (Selleck Chemicals). 
 
Western blot analysis 
To analyze the expression of EBV lytic proteins, NPC and GC cells were treated with 
various concentrations of selective HDAC inhibitors for 48 hr. After treatment, the 
cells were pelleted and washed once with PBS. Proteins from the cell pellets were 
extracted and western blot analyses were performed as described previously.
16
 EBV 
latent and lytic proteins were detected with anti-EBNA1, anti-Zta, anti-Rta, 
anti-BMRF1, anti-VCA p18, and anti-gp350/220 antibodies; cell cycle regulatory 
proteins, were detected with anti-p21
WAF1
, anti-cyclin-B1, anti-p-cdc2, anti-cyclin-D1 
and anti-p-Rb antibodies; histone acetylation was detected with an anti-acetyl-H3 and 
anti-acetyl-H4 antibodies; apoptosis was detected with anti-PARP rabbit polyclonal 
antibody as described previously.
16, 17, 24, 25
 Expression of cellular kinases was detected 
with anti-p-PKC-δ, anti-p-JNK, anti-p-p38 and anti-p-ATM antibodies (1:1000; Cell 
Signaling Technology, Beverly, MA). Expression of human β-actin was detected with 
anti-β-actin antibody (1:10000; Sigma-Aldrich, St. Louis, MO) as a loading control. 
The proteins were visualized with HRP-conjugated anti-mouse IgG (1:5000; Zymed, 
San Francisco, CA), anti-rabbit IgG (1:5000; Zymed, San Francisco, CA) or anti-rat 
IgG (1:5000; Zymed, San Francisco, CA) goat polyclonal antibodies and Pierce ECL 
Western Blotting Detection Reagent (Thermo Fisher Scientific, Rockford, IL). All 
proteins were identified according to their corresponding molecular weights.  
 
Immunocytochemistry  
EBV-positive HA cells grown on cover slips coated with 0.1% gelatin were treated 
with various selective HDAC inhibitors for 48 hr. The cells were fixed with acetone 
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for 10 minutes and then stained with a combination of anti-Zta mouse monoclonal 
(1:50) and anti-VCA-p18 rat polyclonal (1:50) antibodies overnight at 4
o
C. Zta and 
VCA-p18 proteins were visualized with Alexa Fluor 488 goat anti-mouse IgG 
antibody (1:500; Invitrogen, Carlsbad, CA) and Alexa Fluor 594 goat anti-rat IgG 
antibody (1:500; Invitrogen), respectively, under fluorescence microscopy. Nuclei of 
cells were stained with 4',6-diamidino-2-phenylindole (DAPI) (Roche, Mannheim, 
Germany).  
 
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide(MTT) assay 
NPC and GC cells were treated with various concentrations of selective HDAC 
inhibitors for various time points in 96-well cell culture plates and incubated at 37
o
C 
in 5% CO2. MTT assay was performed as previously described.
16
 
 
Nude mice experiment 
HA, SNU-719, HONE1 and C666-1 (1 X 10
7
) cells were resuspended in 200 µl 
serum-free culture medium. The cells were subcutaneously injected at the right flanks 
of female BALB/c nude (nu/nu) at 6-7 weeks of age. When the tumours became 
palpable, 375 or 750 µg/kg romidepsin (days 1 & 4 each week) dissolved in DMSO in 
10 µl was administered to the nude mice of the treatment groups (n=5) by 
intraperitoneal (IP) injection for 4 weeks. Equal volume of DMSO was administered 
to the nude mice of the control group (n=5). For the combination treatment with GCV 
(Roche), 50 mg/kg GCV (5 days per week) dissolved in PBS in 50 µl was 
administered to the mice by IP injection for 4 weeks. The mice were weighed twice 
weekly to assess the toxicity of the drugs. All the mice were euthanized by IP 
injection of 200 mg/kg pentobarbital at the end of experiment, when the control group 
of mice had tumours greater than 1.7 cm in diameter. The size and the weight of the 
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tumours were measured as described previously.
17, 24
 
 
Cell cycle analysis 
HA and AGS-BDneo cells were treated with romidepsin for 12, 24, 48, and 72 hr. The 
treated cells were subjected to cellular DNA content analysis by flow cytometry as 
described previously.
16
 
 
Flow cytometric analysis 
EBV-positive HA and AGS-BDneo cells were treated with various concentrations of 
romidepsin for 5 days. The treated cells were then fixed and stained with 
combinations of LIVE/DEAD fixable aqua dead cell stain kit (Invitrogen, Carlsbad, 
CA), cleaved caspase-3 rabbit monoclonal antibody (1:200) and either anti-Zta (1:50), 
anti-BMRF1 (1:800) or anti-gp350/220 (1:50) mouse monoclonal antibodies 
overnight at 4
o
C. Co-expression of the proteins was detected with Alexa Fluor 488 
goat anti-rabbit IgG (1:500; Invitrogen, Carlsbad, CA) and Alexa Fluor 647 goat 
anti-mouse IgG (1:500; Invitrogen) antibodies using flow cytometry (LSRII, BD 
Biosciences, San Jose, CA) as previously described. Data were analyzed by FlowJo 
software (Tree Star, San Carlos, CA). 
 
Cell viability studies 
EBV-negative and -positive NPC and GC cells were seeded in 24-well cell culture 
plates. Cells grown to 70% confluence were treated with combinations of various 
concentrations of romidepsin and GCV for 7 days. Cell viability was determined by 
trypan blue exclusion assay. 
 
Quantitative PCR assay 
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To quantitate viral DNA replication during induction of EBV lytic cycle in NPC and 
GC cells, HA and AGS-BDneo cells were treated with different concentrations of 
romidepsin for 48 hr. After treatment, the cells were pelleted and washed once with 
PBS. DNA from the cell pellets was extracted and quantitative PCR was performed as 
described previously.
16
 EBV viral load was presented as number of viral genomes per 
cell. Data were determined in triplicate in a 96-well plate format. 
 
EBV infection assay 
To examine the production of infectious viral particles, AGS-BX1 and HONE1-EBV 
cells, which were infected with GFP-expressing recombinant EBV, were treated with 
romidepsin with or without GCV for 5 days. The culture supernatants were collected 
and EBV infection assay was performed as previously described.
16
 
 
Knockdown constructs for HDACs 
A pLKO TRC cloning vector (Addgene no. 10878) mammalian expression lentiviral 
plasmid was used to establish the HDAC-1, -2, and -3 knockdown constructs. For each 
HDAC, two sets of oligonucleotides were utilized to perform knockdown experiments. 
The knockdown constructs were designed according to the information of the Public 
TRC portal: HDAC-1 (TRCN0000195672 and TRCN0000004816), HDAC-2 
(TRCN0000195547 and TRCN0000196590), and HDAC-3 (TRCN0000004825 and 
TRCN0000196267). The scramble vector (Addgene 1864) served as a control. 
 
Statistical analysis 
In vitro experiments were performed in triplicate and repeated at least 3 times. Data 
were analyzed for statistical significance using One-way ANOVA Dunnett’s Multiple 
Comparison Test. P value < 0.05 was considered statistically significant. All statistical 
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analyses were performed with GraphPad Prism Version 5.0 software. 
 
Results: 
The class I HDAC inhibitor romidepsin significantly induced EBV lytic cycle in 
EBV- positive NPC cells 
Pan-HDAC inhibitors, which inhibit eleven HDAC isoforms, were widely 
used to induce EBV lytic cycle in vitro and in clinical study. We have reported that 
SAHA, an FDA approved HDAC inhibitor, can significantly induce EBV lytic cycle 
in EBV-positive epithelial malignancies such as NPC cells.
16, 17
 Interestingly, SAHA, 
which was previously recognized as a pan-HDAC inhibitor, is selective against 
several HDAC isoforms, including HDAC-1, -2, -3, -6 and -8.
26
 We, therefore, set out 
to test several selective HDAC inhibitors for their abilities to induce EBV lytic cycle 
in EBV-positive NPC cells. Expression of an EBV immediate-early lytic protein, Zta, 
was detected as a marker to indicate the induction of EBV lytic cycle in an NPC cell 
line, HA. We found that class I HDAC inhibitors targeting HDAC-1, -2 and -3 
isoforms (romidepsin, MS-275 or apicidin) could significantly induce NPC cells into 
EBV lytic cycle, whereas those targeting HDAC-3, -6 and -8 (droxinostat), HDAC-6 
(Cay10603), or HDAC-8 (PCI34051) could not (Fig 1a). Among the selective HDAC 
inhibitors, romidepsin was the most potent HDAC inhibitor, which can induce EBV 
lytic cycle in more than 70% of cells at nanomolar concentrations (Fig. 1b). 
Romidepsin also induced a comparable level of EBV lytic protein expression and 
histone acetylation at a 2000-fold lower concentration, when compared with SAHA 
(2.5 nM vs 5 µM), whilst it did not cause acetylation of α-tubulin, a substrate of 
HDAC6 (Fig. 1c). These data demonstrated the potency of romidepsin on the 
induction of EBV lytic cycle and specificity of romidepsin against HDAC-1, -2 and -3 
in EBV-positive epithelial cells. 
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Romidepsin inhibited proliferation and induced EBV lytic cycle in multiple 
EBV-positive NPC and GC cell lines 
 We further tested the effects of romidepsin on cell proliferation and EBV lytic 
cycle induction in different NPC and GC cell lines. EBV-positive NPC (HA and 
C666-1) and GC (AGS-BDneo and SNU-719) cells were either untreated (U) or 
treated with romidepsin at different concentrations. After 2 days, the percentage of 
proliferating cells was determined by MTT assay (Supplementary Fig. 1a). The 
proliferations of all these cancer cell lines were inhibited in a dose dependent manner. 
We also analyzed the expression of Zta in these cell lines upon treatment with 
romidepsin by western blotting. Interestingly, we found that romidepsin can potently 
induce EBV lytic cycle in all these cell lines from 600 picomolar to 5 nM 
concentrations (Supplementary Fig. 1b). Among the four EBV-positive epithelial cell 
lines, HA and AGS-BDneo cells are relatively more sensitive to the lytic cycle 
reactivation by romidepsin. In these two cell lines, the expression of Zta could be 
detected upon treatment with romidepsin at non-cytotoxic concentrations. These two 
sensitive cell lines were chosen for subsequent analyses of mechanisms of EBV lytic 
reactivation. 
 
Romidepsin induced EBV lytic cycle and suppressed growth of EBV-positive 
NPC and GC xenografts in nude mice 
  We examined the in vivo effects of romidepsin on NPC and GC cells. HA and 
SNU-719 cells (AGS-BDneo failed to grow in nude mice) were inoculated 
subcutaneously at the right flanks of nude mice. The mice (n=5) were either treated 
with DMSO (vehicle control), 0.375 mg/kg or 0.75 mg/kg romidepsin for days1 & 4 
each week over 4 weeks by intraperitoneal injection (Fig. 2a). No significant weight 
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loss or other apparent toxicity was observed in the nude mice following the drug 
treatment (Fig. 2b). Growth of tumors was measured twice weekly by using a caliper. 
Mean increase in tumor volume of NPC and GC in DMSO vehicle-treated and 
romidepsin-treated mice during the experimental period was shown in Fig. 2c and 2d, 
respectively. Suppression of the NPC and GC tumor growth was first discerned on 
Day 8 and continued through to Day 22 following treatment with romidepsin. On Day 
22, we observed a dose-dependent killing of NPC and GC cells by romidepsin (Fig. 
2e and 2f). Western blot analysis showed that romidepsin could induce the cleavage of 
PARP and expression of Zta in both NPC and GC tumors in the nude mice (Fig. 2g). 
However, the level of Zta expression seemed to be weaker when compared with that 
observed in vitro. It might be due to the reason that most of the tumor cells which 
expressed EBV lytic proteins had already been killed before the detection of Zta at the 
end of the in vivo experiments.  
 
Romidepsin induced acetylation of histone H3 and up-regulation of p21 prior to 
the reactivation of EBV lytic cycle 
Romidepsin is a class I HDAC inhibitor, which can selectively inhibit HDAC-1, 
-2 and -3 isoforms.
27, 28
 Acetylation of histone H3 and up-regulation of p21
WAF1
 are 
two well-known markers following inhibition of HDAC-1, -2 or -3.
29-31
 We compared 
the kinetics of expression of these two markers with those of EBV lytic proteins upon 
treatment with romidepsin by western blotting (Fig. 3a). Expression of EBV 
immediate-early lytic protein (Zta) and early lytic protein (BMRF1) was first detected 
12 hr post-treatment in AGS-BDneo cells and at 24 hr in HA cells. Expression of EBV 
late lytic protein, gp350/220, was clearly detected in HA cells at 48 hr post-treatment, 
whilst that in AGS-BDneo was only barely detected. Interestingly, both acetylation of 
histone H3 and up-regulation of p21
WAF1
 were observed prior to the expression of Zta. 
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The up-regulation of p21
WAF1
, which is a cyclin-dependent kinase inhibitor, led to 
down-regulation of several cell cycle regulatory proteins (cyclin B1, p-cdc2, cyclin 
D1 and p-Rb) and subsequent cell cycle arrest at G2/M phase in both HA and 
AGS-BDneo cells (Fig. 3b). Collectively, our data suggest that the effects of HDAC 
inhibition, including histone acetylation and p21
WAF1
 up-regulation, could be observed 
prior to the reactivation of EBV lytic cycle. 
 
Induction of EBV lytic cycle was abrogated by a specific inhibitor of PKC-δ but 
not the inhibitors of PI3K, MEK, p38 MAPK, JNK or ATM pathways 
 We attempted to further characterize the mechanisms of EBV lytic cycle 
reactivation by romidepsin. Various reports showed that the phosphatidylinositol 
3’-kinase (PI3K), MAPK/ERK kinase (MEK), c-Jun amino terminal kinase (JNK), 
p38 stress mitogen-activated protein kinase (MAPK), ataxia telangiectasia-mutated 
(ATM) kinase, and protein kinase C-delta (PKC-δ) pathways were involved in EBV 
lytic cycle induction.
4, 5, 32-37
 We, therefore, examined the roles of these pathways in 
the romidepsin’s induction of EBV lytic cycle by using specific pathway blockers (Fig. 
4a and 4b). HA and AGS-BDneo cells were pre-treated with either 15 µM LY294002 
(PI3K inhibitor), 50 µM PD98059 (MEK inhibitor), 50 µM SP600125 (JNK inhibitor), 
20 µM SB202190 (p38 MAPK inhibitor) or 10 µM rottlerin (PKC-δ inhibitor) for 1 hr, 
followed by incubation with romidepsin for 24 hr. Expression of EBV lytic proteins, 
including Zta and Rta, in the HA and AGS-BDneo cells were examined by western 
blot analysis. Only rottlerin, but not other pathway blockers, was able to inhibit the 
expression of EBV lytic proteins, indicating that PKC-δ, rather than the PI3K, MEK, 
JNK, and p38 MAPK pathways, was required for EBV lytic cycle reactivation by 
romidepsin. We further found that rottlerin could suppress the expression of early lytic 
protein BMRF1 and up-regulation of p21
WAF1
 (Fig. 4c). In the same experiment, 
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rottlerin could specifically reduce the phosphorylation of PKC-δ but not other kinases 
such as JNK and p38 MAPK. We also analyzed the effect of pharmacological 
inhibition of ATM pathway by KU-55933 (Fig. 4d). Our data showed that KU-55933 
could effectively reduce the phosphorylation of ATM expression in both HA and 
AGS-BDneo cells. However, inhibition of the ATM pathway could only weakly affect 
the expression of Zta. Taken together, our results suggest that only PKC-δ, but not 
other reported pathways, was involved in the reactivation of EBV lytic cycle by 
romidepsin. 
 
Romidepsin dose-dependently induced co-expression of EBV lytic protein and 
cell death marker in both NPC and GC cells 
We have previously reported that induction of EBV lytic cycle by HDAC 
inhibitors could mediate enhanced killing of EBV-positive NPC and GC cells.
16, 17
 
Here, we investigated the co-expression of cleaved caspase-3 and EBV lytic protein in 
the HA and GC cells upon treatment with increasing concentrations of romidepsin for 
5 days by flow cytometry. We found that romidepsin could dose-dependently induce 
the co-expression of EBV lytic proteins (Zta, BMRF1, and gp350/220) in both HA 
and AGS-BDneo cells. At 2.5 and 5 nM romidepsin, the percentages of AGS-BDneo 
and HA cells co-expressing cleaved caspase-3 and Zta were 50.9% and 24.4%, 
respectively (Fig. 5a and 5b). The data indicated that the majority of cells expressing 
EBV lytic proteins were undergoing apoptosis. Upon the same treatment, there were 
27.1% of AGS-BDneo and 26.2% of HA cells expressed cleaved caspase-3 but not 
Zta. These apoptotic populations probably represented the cells killed directly by the 
general toxicity of romidepsin to cancer cells. Interestingly, upon treatment with 
relatively non-toxic concentrations of romidepsin in the GC and NPC cells (0.625 nM 
in AGS-BDneo and 1.25 nM in HA), there were high percentages of cells expressing 
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Zta without cleaved caspase-3 (34.7% in AGS-BDneo and 10.6% in HA). These 
concentrations would be interesting for the investigation of combinatorial effect with 
anti-viral agents such as ganciclovir (GCV). We also stained dying AGS-BDneo and 
HA cells with aqua blue dye prior to staining for Zta, BMRF1 or gp350/220, which 
showed similar results to those of caspase-3 and lytic protein’s co-staining (Fig. 5c 
and 5d). When we compared the effect of romidepsin with another FDA-approved 
HDAC inhibitor SAHA, we found that romidepsin can induce similar percentages of 
cells to co-express EBV lytic protein and cleaved caspase-3 at a 2000-fold lower 
concentration (Fig. 5e). These data suggest the potential application of romidepsin for 
the treatment of EBV-associated cancers. 
 
Inhibition of HDAC-1, -2, or -3 by romidepsin conferred susceptibility of 
EBV-positive epithelial malignancies to ganciclovir treatment 
 Studies have shown that induction of EBV lytic cycle could confer susceptibility 
of EBV-associated cancer to treatment with ganciclovir.
5, 6, 8, 38
 In this study, we also 
investigated the effect of combination of romidepsin and ganciclovir on the killing of 
EBV-negative and EBV-positive NPC and GC cells (Fig. 6a and 6b). According to our 
data, treatment with romidepsin alone was sufficient to induce enhanced killing of 
EBV-positive HA and AGS-BDneo cells, when compared with their EBV-negative 
counterparts. Interestingly, romidepsin could also confer susceptibility of the 
EBV-positive epithelial cells to the treatment with ganciclovir. Of note, the 
concentrations of romidepsin, which induced the expression of EBV lytic proteins 
without causing substantial cell death (refer to Fig. 5a and 5b), could mediate the most 
significant combinatorial killing effects with ganciclovir. We also analyzed the viral 
DNA replication and infectious virus production by quantitative PCR and EBV 
infection assays, respectively. Our data showed that treatment with ganciclovir could 
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effectively suppress the viral DNA replication and infectious virus production induced 
by romidepsin (Fig. 6c and 6d). The weak virion production in AGS-BX1 cells 
corresponds to the relatively weak expression level of EBV late lytic protein upon 
treatment with 2.5 nM romidepsin (refer to Fig. 5a). We also tested the anti-tumor 
effects of combination of romidepsin and GCV on different EBV-negative and 
-positive xenografts in nude mice (Fig. 6e). Our data showed that combination of 
romidepsin and GCV, when compared with either drug alone, mediated enhanced 
growth suppression of EBV-positive xenografts (HA, C666-1 and SNU-719). 
However, such enhanced growth suppression by combination of romidepsin and GCV 
could not be observed in EBV-negative xenografts (HONE1). To assess the toxicity of 
the drug combination, we measured the weight of mice throughout the period of drug 
treatment and observed no significant weight loss in the mice treated with 
combination of romidepsin and GCV or either drug alone (Fig. 6f). To investigate 
whether the enhanced killing by combination of romidepsin and GCV is related to 
inhibition of HDAC-1, -2 or -3, we performed short hairpin RNA (shRNA) 
knockdown experiments to individually knockdown either HDAC-1, -2 or -3 and 
analyzed the reactivation of EBV lytic cycle and susceptibility of EBV-positive cells 
to GCV (Fig. 6g and 6h). We found that knockdown of either HDAC-1, -2 or -3 could 
be sufficient to induce the expression of Zta in HA cells. Our data also showed that 
GCV could induce significant percentages of cell death in cells transfected with 
shRNA targeting either HDAC-1, -2, or -3. Collectively, our data demonstrated that 
inhibition of HDAC-1, -2 and -3 by romidepsin was sufficient to induce EBV lytic 
cycle and confer susceptibility of EBV-positive epithelial cells to the treatment with 
ganciclovir. 
 
Discussion: 
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 Pharmacological reactivation of EBV into lytic cycle from its latency is being 
explored as a potential therapeutic strategy against the EBV-associated diseases.
4-8
 
Pan-HDAC inhibitors, which inhibit eleven HDAC isoforms, are widely used to 
induce EBV lytic cycle in EBV-associated cancer cells in vitro and in clinical trials.
4-8
 
We have also reported that pan-HDAC inhibitors including trichostatin A, VPA, 
sodium butyrate, and SAHA, could induce EBV lytic cycle in EBV-positive epithelial 
malignancies, including NPC and GC, and mediate enhanced cell death.
16, 17
 Newly 
synthesized selective HDAC inhibitors, which target different combinations of 
specific HDAC isoforms, were reported to have more potent effects than pan-HDAC 
inhibitors against different types of cancers.
27, 28
 In this study, we hypothesized that 
inhibition of one or several specific HDAC isoforms by selective HDAC inhibitors 
could more potently induce EBV lytic cycle in EBV-positive NPC and GC cells. 
Among the selective HDAC inhibitors we have tested, romidepsin, which is 
FDA-approved for the treatment of cutaneous T-cell lymphoma and peripheral T-cell 
lymphoma,
15
 was found to be the most potent lytic cycle inducer. It could activate 
early phase of EBV lytic cycle at ~0.5 to 5 nM. These concentrations are much lower 
than the clinically achievable concentration in patients’ plasma, which is around 800 
nM.
28
 We further tested the effect of romidepsin in vivo and found that romidepsin 
could also significantly induce EBV lytic cycle and suppress the growth of NPC and 
GC xenografts in nude mice. All these preclinical data suggest the potential 
application of romidepsin for the treatment of EBV-associated cancers such as NPC 
and GC. 
 Although HDAC inhibitors have been widely used to induce EBV lytic cycle in 
various types of cancer cells, the essential role of HDAC inhibition in the regulation 
of EBV lytic cycle reactivation is still unknown. According to our data, only the 
HDAC inhibitors targeting HDAC-1, -2 and -3 (romidepsin, MS-275 or apicidin) 
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could significantly induce EBV lytic cycle in NPC cells. To further evaluate the 
involvement of HDAC inhibition on EBV lytic reactivation, we examined the 
expression kinetics of two typical markers of inhibition of HDAC-1, -2 and -3, 
including the acetylation of histone H3 and up-regulation of p21
WAF1
, upon treatment 
with romidepsin. Both acetylation of histone H3 and up-regulation of p21
WAF1
 were 
observed prior to the reactivation of EBV lytic cycle. The up-regulation of p21
WAF1
 
also led to the down-regulation of several cell cycle regulatory proteins and 
subsequent cell cycle arrest at G2/M phase, suggesting a potential link between the 
G2/M arrest and the reactivation of EBV lytic cycle. Liu et al. also recently reported 
that nocodazole, which could induce mitotic arrest in various types of cell lines, could 
reactivate EBV lytic cycle in NPC cells.
39
 The exact relationship of cell cycle arrest 
and lytic cycle reactivation in EBV-positive cancer cells deserves further investigation. 
To further evaluate the role of HDAC inhibition in the lytic reactivation by HDAC 
inhibitors, we performed shRNA knockdown experiments to specifically inhibit 
HDAC-1, -2 and -3. Interestingly, we found that inhibition of either HDAC-1, -2 or -3 
was sufficient to induce EBV lytic cycle in the EBV-positive epithelial malignancies. 
The data is consistent with the reported finding that overexpression of HDAC-2 could 
suppress the lytic cycle reactivation in NPC cells by HDAC inhibitors.
35
 We also 
observed that class I HDACs such as HDAC-2 and -3 were overexpressed in various 
EBV-positive epithelial cells, when compared with lymphoma cells (unpublished 
data). The data might explain the previously reported differential responses of 
epithelial cells and lymphoma cells towards lytic cycle reactivation by HDAC 
inhibitors.
16, 40
 
 To further investigate the mechanisms of EBV lytic cycle reactivation by 
romidepsin, we examined several kinase pathways, including the PI3K/Akt, ERK, 
JNK, p38 MAPK, ATM and PKC-δ pathways
4, 5, 32-37
 which were demonstrated to 
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regulate EBV lytic cycle in various cancer cell types. We found that only 
pharmacological inhibition of PKC-δ, rather than the PI3K, MEK (activator of ERK), 
JNK, p38 MAPK, and ATM pathways, could significantly inhibit the EBV lytic cycle 
reactivation by romidepsin. The PKC-δ pathway has an established role in induction 
of lytic cycle upon treatment by HDAC inhibitors in EBV-positive epithelial cancer 
cells. For instance, Tsai et al. has shown that the activation of PKC-δ and Sp1 was 
required for the lytic cycle reactivation in NPC cells by HDAC inhibitors.
35
 Feng et al. 
also showed that PI3K, p38 MAPK, and PKC-δ signaling were involved in EBV lytic 
cycle induction in GC cells following treatment with 5-FU and cisplatin.
5
 However, 
the involvement of cellular pathways in mediating lytic induction seems to be varying 
in different cell types and upon treatment with different stimuli. For instance, 
although the ATM pathway was shown to be crucial for the regulation of EBV lytic 
cycle reactivation,
36
 other findings have also suggested that ATM was only involved 
in the stage of viral DNA replication rather than the initial step of lytic reactivation.
41, 
42
 Our data seem to support the latter argument since ATM inhibitor did not abrogate 
the lytic cycle reactivation by romidepsin in both NPC and GC cell lines in the 
present study (refer to Fig. 5d). More investigations are still required to reconcile such 
contradictory data and further elucidate the mechanisms of EBV lytic cycle induction 
in EBV-positive epithelial cells. 
 Because romidepsin could potently induce EBV lytic cycle in vitro and in vivo, 
we further evaluated the potential clinical value of using romidepsin for lytic 
induction therapy in EBV-positive epithelial malignancies. We found that romidepsin 
could induce co-expression of Zta and cleaved caspase-3 in a significant proportion of 
cells, suggesting the majority of cells induced into early phase of EBV lytic cycle 
would eventually proceed to cell death. We also found that induction of EBV lytic 
cycle by romidepsin could mediate enhanced killing of EBV-positive cells versus their 
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EBV-negative counterparts. These findings are similar to those observed in NPC cells 
upon treatment with SAHA.
16, 17
 However, romidepsin could induce EBV lytic cycle 
in a high percentage of cells at 2000-fold lower concentration when compared with 
SAHA. Moreover, in contrast to the effect of SAHA, romidepsin was able to induce 
EBV lytic cycle in EBV-positive epithelial cells at concentrations that were not 
cytotoxic to the cells. These two properties would favor the application of romidepsin 
for the scientific investigation of EBV life cycle and clinical treatment of 
EBV-associated cancers. Since induction of EBV lytic cycle was shown to confer 
susceptibility of EBV-associated cancer to treatment with GCV,
5, 6, 8, 38
 we also 
investigated the combinatorial effect of romidepsin and GCV in vitro and in vivo. Our 
in vitro data showed that romidepsin, especially when administered at non-cytotoxic 
concentrations, could induce much enhanced killing of EBV-positive NPC and GC 
cells when combined with ganciclovir. The drug combination, when compared with 
either drug alone, could also mediate stronger growth suppression of EBV-positive 
NPC and GC xenografts in nude mice. While exerting potent cytotoxic effects with 
romidepsin in the EBV-positive cancer cells, GCV significantly suppressed the viral 
replication in the cancer cells, thus could serve to minimize the production of the 
potentially harmful oncogenic virus in the patients.  
 In conclusion, this is the first study to demonstrate that romidepsin could 
potently induce EBV lytic cycle through inhibition of HDAC-1, -2 or -3 and confer 
cytotoxicity of GCV in EBV-positive epithelial malignancies. The data suggest further 
application of romidepsin for the investigation of EBV lytic cycle reactivation and 
clinical treatment of EBV-associated cancers. 
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Figure legends: 
Figure 1. Inhibition of HDAC-1/-2/-3, but not HDAC-6/-8, by selective class I 
HDAC inhibitors (e.g. romidepsin) was sufficient to induce EBV lytic cycle in 
NPC cells. (a) HA cells were treated with increasing concentrations of either apicidin 
(HDAC1-3), MS-275 (HDAC1-3), romidepsin (HDAC1-3), droxinostat (HDAC-3,-6 
and -8), cay10603 (HDAC-6), PCI34051 (HDAC-8) or 5 µM SAHA (HDAC1-3,-6 
and -8) for 48 hr. Expression of an immediate-early lytic protein of EBV, Zta, was 
analyzed by western blotting. (b) HA cells were treated with either 1.25 µM Apicidin, 
2.5 µM MS-275, 2.5 nM romidepsin, 25 µM droxinostat, 2 nM Cay10603 or 20 µM 
PCI34051 for 48 hr. Expression of Zta (green signals) and a late lytic protein of EBV, 
VAC-p18, (red signals) was analyzed by immunofluorescence staining. DAPI (blue 
signals) stained cell nuclei. (c) HA and BD-neo cells were treated with either 5 µM 
SAHA or 2.5 nM romidepsin for 48 hr. Expression of EBV lytic protein, Zta, and 
cellular proteins, acetyl-histone H4 and acetyl-α-tubulin (substrate inhibited by 
HDAC 6), was analyzed by western blotting. Cellular α-tubulin served as loading 
control. 
 
Figure 2. Romidepsin induced EBV lytic cycle and suppressed growth of NPC 
xenografts in nude mice. Five million HA NPC or SNU-719 GC cells resuspended in 
100 µl RPMI were subcutaneously injected into the right flanks of nude mice. One 
week later (when the tumors were palpable), the mice were either treated with DMSO, 
0.375 or 0.75 mg/kg romidepsin for 2 days/week over 4 weeks by intraperitoneal 
injection. (a) Resected tumours of mice of control and romidepsin-treated groups 
were illustrated. (b) The weights of mice of control and romidepsin-treated groups 
were shown. (c & d) The size of tumors (HA and SNU-719) during the period of 
experiment was measured twice weekly using a caliper. Data are presented as the 
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mean tumor volumes of mice in both treatment and control groups on the days 
post-treatment. (e & f) Average tumor masses (HA and SNU-719) of mice of control 
and romidepsin-treated groups were shown. Error bars represent the standard error of 
mean (SEM) of tumor masses. (g) Protein samples extracted from the tumors were 
tested for expression of PARP and Zta proteins by western blot analysis. Cellular 
α-tubulin served as loading control. 
 
Figure 3. Romidepsin induced the expressison of p21
WAF1
 and G2/M arrest in 
NPC and GC cells prior to EBV lytic cycle reactivation. HA and AGS-BDneo cells 
were treated with 5 or 2.5 nM romidepsin, respectively, for 0, 1, 2, 4, 8, 12, 24, 48 and 
72 hr. (a) The kinetics of expression of the EBV lytic proteins including EBV 
immediate-early (Zta), early (BMRF1) and late (VCA p-18 and gp350/220); EBV 
latent protein EBNA1; cellular acetyl-H3, p21
WAF1
, cyclin-B1, p-cdc2, cyclin-D1 and 
p-Rb was analyzed by western blotting. α-tubulin was detected as a loading control. 
(b) Cell cycle status was analyzed by flow cytometry. 
 
Figure 4. The up-regulation of p21
WAF1
 and induction of EBV lytic cycle were 
abrogated by a specific inhibitor of PKC-δ but not the inhibitors of PI3K, MEK, 
JNK, p38 MAPK or ATM pathways. (a) HA and (b) AGS-BDneo cells were 
pre-treated with either 15 µM LY294002 (PI3K inhibitor), 50 µM PD98059 (MEK 
inhibitor), 50 µM SP600125 (JNK inhibitor), 20 µM SB202190 (p38 MAPK inhibitor) 
or 10 µM rottlerin (PKC-δ inhibitor) for 1 hr, and then incubated with 2.5 (for 
AGS-BDneo) or 5 nM (for HA) romidepsin for 48 hr. Expression of EBV lytic 
proteins, including Zta and Rta, and acetyl-histone H3 proteins, were analyzed by 
western blot analysis. (c) HA and AGS-BDneo cells were pre-treated with 10 µM 
rottlerin or (d) 10 µM KU-55933 (ATM inhibitor) for 1 hr before treatment with 5 nM 
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romidepsin for 48 hr. Expression of EBV proteins, including Zta, Rta and BMRF1, 
and cellular proteins including p21
WAF1
, p-PKC-δ, p-JNK and p-p38 were analyzed by 
western blotting. α-tubulin was detected as a loading control. 
 
Figure 5. Romidepsin induced co-expression of EBV lytic proteins and cleaved 
caspase-3 in EBV-positive epithelial cells. AGS-BDneo and HA cells were treated 
with 0.625, 1.25, 2.5 and 5 nM romidepsin for 5 days. Flow cytometric analysis was 
performed to quantify the percentages of (a) AGS-BDneo and (b) HA cells 
co-expressed either Zta, BMRF1 or gp350/220 and cleaved caspase-3. Following the 
same treatment, flow cytometric analysis was performed to quantify the percentages 
of live (aqua blue -) or dead (aqua blue +) (c) AGS-BDneo and (d) HA cells cells 
which expressed Zta, BMRF1 or gp350/220. (e) AGS-BDneo cells were treated with 
either 2.5/5 nM romidepsin or 2.5/5 µM SAHA for 5 days. Flow cytometric analysis 
was performed to quantify the percentages of cells expressed Zta and cleaved 
caspase-3 or incorporated aqua blue dye. 
 
Figure 6. Romidepsin conferred susceptibility of EBV-positive epithelial cancer 
cells to the treatment with ganciclovir. EBV-negative and -positive NPC (HONE1 
and HA) and GC (AGS and AGS-BDneo) cells were treated with increasing 
concentrations of romidepsin, 10 µg/ml GCV or their combinations for 7 days or 
untreated. Number of viable (a) NPC and (b) GC cells was determined by trypan blue 
exclusion assay. Results are presented as percentages of viable cell populations among 
treated cells compared with those of untreated control. Error bars represent the 
standard error of mean (SEM) of data obtained in at least three independent 
experiments. (c) HA and AGS-BDneo cells were treated with either romidepsin (2.5 
and 5 nM for AGS-BDneo and HA, respectively), 10 µg/ml GCV or their combination 
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for 3 days. Quantitative PCR was performed to analyze the induction of EBV DNA 
replication in both HA and AGS-BDneo cells. Data are presented as number of viral 
genomes per cell. (d) HONE1-EBV and AGS-BX1 cells were treated with either 
romidepsin (2.5 and 5 nM for AGS-BX1 and HONE1-EBV, respectively), 10 µg/ml 
GCV or their combination for 5 days. EBV infection assay was performed to analyze 
the production of infectious viral particle. Culture supernatants, which would contain 
GFP-expressing recombinant EBV particles released by HONE1-EBV and AGS-BX1 
cells, were used to infect Daudi cells for 48 hr. The amount of infectious EBV 
particles was estimated by the level of GFP expression detected by flow cytometry. 
The shaded areas represent the percentage of Daudi cells infected with fresh medium. 
The open areas represent the percentage of Daudi cells infected with medium cultured 
with HONE1-EBV and AGS-BX1 cells upon treatment with either romidepsin, GCV 
or their combination. (e) Five million HONE1, HA, C666-1 or SNU-719 GC cells 
resuspended in 100 µl RPMI were subcutaneously injected into the right flanks of 
nude mice. When the tumours were palpable, the mice were either treated with 0.375 
mg/kg romidepsin for 2 days/week, 50 mg/kg GCV for 5 days/week, or their 
combination over 4 weeks by intraperitoneal injection. Percentages of tumor masses 
of mice of the treatment groups when compared with the control group were shown. 
Error bars represent the standard error of mean (SEM) of tumor masses. (f) The 
weights of mice of control and treatment groups were shown. (g) HA cells were stably 
infected with 2 sets of shRNA oligonucleotides targeting HDAC-1, -2 or -3 or 
scramble shRNA control vector. Western blotting was performed to analyze the 
expression of HDAC-1, -2, -3 and Zta in the stable knockdown cell lines. (h) The 
stable knockdown cell lines were treated with 10 µg/ml GCV for 7 days or untreated. 
Number of viable cells was determined by trypan blue exclusion assay. 
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Figure 1. Inhibition of HDAC-1/-2/-3, but not HDAC-6/-8, by selective class I HDAC inhibitors (e.g. 
romidepsin) was sufficient to induce EBV lytic cycle in NPC cells. (a) HA cells were treated with increasing 
concentrations of either apicidin (HDAC1-3), MS-275 (HDAC1-3), romidepsin (HDAC1-3), droxinostat 
(HDAC-3,-6 and -8), cay10603 (HDAC-6), PCI34051 (HDAC-8) or 5 µM SAHA (HDAC1-3,-6 and -8) for 48 
hr. Expression of an immediate-early lytic protein of EBV, Zta, was analyzed by western blotting. (b) HA 
cells were treated with either 1.25 µM Apicidin, 2.5 µM MS-275, 2.5 nM romidepsin, 25 µM droxinostat, 2 nM 
Cay10603 or 20 µM PCI34051 for 48 hr. Expression of Zta (green signals) and a late lytic protein of EBV, 
VAC-p18, (red signals) was analyzed by immunofluorescence staining. DAPI (blue signals) stained cell 
nuclei. (c) HA and BD-neo cells were treated with either 5 µM SAHA or 2.5 nM romidepsin for 48 hr. 
Expression of EBV lytic protein, Zta, and cellular proteins, acetyl-histone H4 and acetyl-α-tubulin (substrate 
inhibited by HDAC 6), was analyzed by western blotting. Cellular α-tubulin served as loading control.  
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Figure 2. Romidepsin induced EBV lytic cycle and suppressed growth of NPC xenografts in nude mice. Five 
million HA NPC or SNU-719 GC cells resuspended in 100 µl RPMI mixed with matrigel were subcutaneously 
injected into the right flanks of nude mice. One week later (when the tumors were palpable), the mice were 
either treated with DMSO, 0.375 or 0.75 mg/kg romidepsin for 2 days/week over 4 weeks by intraperitoneal 
injection. (a) Resected tumours of mice of control and romidepsin-treated groups were illustrated. (b) The 
weights of mice of control and romidepsin-treated groups were shown. (c & d) The size of tumors (HA and 
SNU-719) during the period of experiment was measured twice weekly using a caliper. Data are presented 
as the mean tumor volumes of mice in both treatment and control groups on the days post-treatment. (e & 
f) Average tumor masses (HA and SNU-719) of mice of control and romidepsin-treated groups were shown. 
Error bars represent the standard error of mean (SEM) of tumor masses. (g) Protein samples extracted from 
the tumors were tested for expression of PARP and Zta proteins by western blot analysis. Cellular α-tubulin 
served as loading control.  
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Figure 3. Romidepsin induced the expressison of p21WAF1 and G2/M arrest in NPC and GC cells prior to EBV 
lytic cycle reactivation. HA and AGS-BDneo cells were treated with 5 or 2.5 nM romidepsin, respectively, for 
0, 1, 2, 4, 8, 12, 24, 48 and 72 hr. (a) The kinetics of expression of the EBV lytic proteins including EBV 
immediate-early (Zta), early (BMRF1) and late (VCA p-18 and gp350/220); EBV latent protein EBNA1; 
cellular acetyl-H3, p21WAF1, cyclin-B1, p-cdc2, cyclin-D1 and p-Rb was analyzed by western blotting. α-
tubulin was detected as a loading control. (b) Cell cycle status was analyzed by flow cytometry.  
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Figure 4. The up-regulation of p21WAF1 and induction of EBV lytic cycle were abrogated by a specific 
inhibitor of PKC-δ but not the inhibitors of PI3K, MEK, JNK, p38 MAPK or ATM pathways. (a) HA and (b) 
AGS-BDneo cells were pre-treated with either 15 µM LY294002 (PI3K inhibitor), 50 µM PD98059 (MEK 
inhibitor), 50 µM SP600125 (JNK inhibitor), 20 µM SB202190 (p38 MAPK inhibitor) or 10 µM rottlerin (PKC-δ 
inhibitor) for 1 hr, and then incubated with 2.5 (for AGS-BDneo) or 5 nM (for HA) romidepsin for 48 hr. 
Expression of EBV lytic proteins, including Zta and Rta, and acetyl-histone H3 proteins, were analyzed by 
western blot analysis. (c) HA and AGS-BDneo cells were pre-treated with 10 µM rottlerin or (d) 10 µM KU-
55933 (ATM inhibitor) for 1 hr before treatment with 5 nM romidepsin for 48 hr. Expression of EBV proteins, 
including Zta, Rta and BMRF1, and cellular proteins including p21WAF1, p-PKC-δ, p-JNK and p-p38 were 
analyzed by western blotting. α-tubulin was detected as a loading control.  
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Figure 5. Romidepsin induced co-expression of EBV lytic proteins and cleaved caspase-3 in EBV-positive 
epithelial cells. AGS-BDneo and HA cells were treated with 0.625, 1.25, 2.5 and 5 nM romidepsin for 5 days. 
Flow cytometric analysis was performed to quantify the percentages of (a) AGS-BDneo and (b) HA cells co-
expressed either Zta, BMRF1 or gp350/220 and cleaved caspase-3. Following the same treatment, flow 
cytometric analysis was performed to quantify the percentages of live (aqua blue -) or dead (aqua blue +) 
(c) AGS-BDneo and (d) HA cells cells which expressed Zta, BMRF1 or gp350/220. (e) AGS-BDneo cells were 
treated with either 2.5/5 nM romidepsin or 2.5/5 µM SAHA for 5 days. Flow cytometric analysis was 
performed to quantify the percentages of cells expressed Zta and cleaved caspase-3 or incorporated aqua 
blue dye.  
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Figure 6. Romidepsin conferred susceptibility of EBV-positive epithelial cancer cells to the treatment with 
ganciclovir. EBV-negative and -positive NPC (HONE1 and HA) and GC (AGS and AGS-BDneo) cells were 
treated with increasing concentrations of romidepsin, 10 µg/ml GCV or their combinations for 7 days or 
untreated. Number of viable (a) NPC and (b) GC cells was determined by trypan blue exclusion assay. 
Results are presented as percentages of viable cell populations among treated cells compared with those of 
untreated control. Error bars represent the standard error of mean (SEM) of data obtained in at least three 
independent experiments. (c) HA and AGS-BDneo cells were treated with either romidepsin (2.5 and 5 nM 
for AGS-BDneo and HA, respectively), 10 µg/ml GCV or their combination for 3 days. Quantitative PCR was 
performed to analyze the induction of EBV DNA replication in both HA and AGS-BDneo cells. Data are 
presented as number of viral genomes per cell. (d) HONE1-EBV and AGS-BX1 cells were treated with either 
romidepsin (2.5 and 5 nM for AGS-BX1 and HONE1-EBV, respectively), 10 µg/ml GCV or their combination 
for 5 days. EBV infection assay was performed to analyze the production of infectious viral particle. Culture 
supernatants, which would contain GFP-expressing recombinant EBV particles released by HONE1-EBV and 
AGS-BX1 cells, were used to infect Daudi cells for 48 hr. The amount of infectious EBV particles was 
estimated by the level of GFP expression detected by flow cytometry. The shaded areas represent the 
percentage of Daudi cells infected with fresh medium. The open areas represent the percentage of Daudi 
cells infected with medium cultured with HONE1-EBV and AGS-BX1 cells upon treatment with either 
romidepsin, GCV or their combination. (e) Five million HONE1, HA, C666-1 or SNU-719 GC cells 
resuspended in 100 µl RPMI were subcutaneously injected into the right flanks of nude mice. When the 
tumours were palpable, the mice were either treated with 0.375 mg/kg romidepsin for 2 days/week, 50 
mg/kg GCV for 5 days/week, or their combination over 4 weeks by intraperitoneal injection. Percentages of 
tumor masses of mice of the treatment groups when compared with the control group were shown. Error 
bars represent the standard error of mean (SEM) of tumor masses. (f) The weights of mice of control and 
treatment groups were shown. (g) HA cells were stably infected with 2 sets of shRNA oligonucleotides 
targeting HDAC-1, -2 or -3 or scramble shRNA control vector. Western blotting was performed to analyze 
the expression of HDAC-1, -2, -3 and Zta in the stable knockdown cell lines. (h) The stable knockdown cell 
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trypan blue exclusion assay.  
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